Merck & Company Inc (MRK)

Currency in USD
149.54
-3.56(-2.33%)
Closed·
149.540.00(0.00%)
·
MRK is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
149.02152.08
52 wk Range
77.58156.92
Key Statistics
Prev. Close
153.1
Open
149.65
Day's Range
149.02-152.08
52 wk Range
77.58-156.92
Volume
6.59M
Average Vol. (3m)
10.87M
1-Year Change
77.8756%
Book Value / Share
16.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
148.73
Downside
-0.54%
Members' Sentiments
Bearish
Bullish
ProTips
13 analysts have revised their earnings downwards for the upcoming period

Merck & Company Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

20 Buy
8 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 148.73
(-0.54% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wolfe Research
Buy180.00+20.37%155.00MaintainAug 25, 2026
Goldman Sachs
Buy160.00+6.99%140.00MaintainAug 20, 2026
BMO Capital
Buy170.00+13.68%142.00MaintainAug 20, 2026
Guggenheim
Buy146.00-2.37%-MaintainAug 20, 2026
RBC Capital
Hold150.00+0.31%142.00DowngradeAug 20, 2026

Merck & Company Inc SWOT Analysis


Acquisition Strategy
Cidara's CD388 influenza antiviral presents substantial upside, with peak US sales forecasts reaching $8.4 billion versus consensus estimates
Beyond Keytruda
Patent extension to November 2029 provides runway as sotatercept emerges as potential blockbuster therapy for pulmonary hypertension patients
Price Targets
Analysts project targets ranging from $125 to $140, with multiple upgrades reflecting confidence in post-Keytruda growth trajectory
Pipeline Powerhouse
Merck navigates critical transition with strategic acquisitions adding over $20 billion in peak sales potential across diverse therapeutic areas
Read full SWOT analysis

Merck & Company Inc Earnings Call Summary for Q2/2026

  • Merck Q2 2026 revenue rose 5% to $16.6B, beating estimates; adjusted EPS loss of $0.13 topped forecast loss of $0.27 amid broad portfolio growth.
  • Company raised FY 2026 guidance to $66.3B-$67.3B revenue and $2.66-$2.76 EPS; expects faster-than-anticipated pipeline progress this year.
  • $5.7B Terns Pharmaceuticals acquisition charge weighed on reported results; deal adds MK-4208 asset to strengthen post-KEYTRUDA portfolio diversification.
  • KEYTRUDA sales grew 4% to $8.4B; CEO Davis projects patent cliff will be 'shallow dip with fast return' supported by 20+ new products worth $70B opportunity.
  • Newly approved LIPFENDRA oral PCSK9 inhibitor targets cardiometabolic expansion; WINREVAIR jumped 75% to $588M as launches offset margin pressure concerns.
Last Updated: 08/04/2026, 10:47 AM
Read Full Transcript
Merck&Co investor slides for Q2/2026
Merck Q2 2026 slides
Last Update: Aug 04, 2026
See full investor slides

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
-0.13 / -0.27
Revenue / Forecast
16.6B / 16.41B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.27%
Dividend Yield
2.22%
Industry Median 2.24%
Annualized Payout
3.40
Paid quarterly
5-Years Growth
+5.67%
Growth Streak

MRK Income Statement

Compare MRK to Peers and Sector

Metrics to compare
MRK
Peers
Sector
Relationship
P/E Ratio
116.8x21.6x−0.4x
PEG Ratio
−1.46−0.200.00
Price / Book
8.8x3.6x2.6x
Price / LTM Sales
5.6x2.0x3.1x
Upside (Analyst Target)
−0.7%0.0%46.0%
Fair Value Upside
Unlock6.7%5.3%Unlock

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Employees
74000

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.07B43.53%164.41B
Other Institutional Investors
937.13M37.98%143.47B
Public Companies & Retail Investors
456.17M18.49%69.84B
Total
2.47B100.00%377.72B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.20%226,999,83734,753,675
Vanguard Capital Management, LLC7.10%175,192,48326,821,969

People Also Watch

138.44
NOW
+10.05%
1,484.93
SNDK
-0.96%
255.21
ARM
+1.65%
504.96
MSFT
+1.73%
241.42
MRVL
-1.51%

FAQ

What Is the Merck&Co (MRK) Stock Price Today?

The Merck&Co stock price today is 149.54 USD.

What Stock Exchange Does Merck&Co Trade On?

Merck&Co is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Merck&Co?

The stock symbol for Merck&Co is "MRK."

Does Merck&Co Pay Dividends? What’s The Current Dividend Yield?

The Merck&Co dividend yield is 2.22%.

What Is the Merck&Co Market Cap?

As of today, Merck&Co market cap is 370.32B USD.

What Is Merck&Co's Earnings Per Share (TTM)?

The Merck&Co EPS (TTM) is 1.27.

When Is the Next Merck&Co Earnings Date?

Merck&Co will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is MRK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Merck&Co Stock Split?

Merck&Co has split 5 times.

How Many Employees Does Merck&Co Have?

Merck&Co has 74000 employees.

What is the current trading status of Merck&Co (MRK)?

As of Aug 27, 2026, Merck&Co (MRK) is trading at a price of 149.54 USD, with a previous close of 153.10 USD. The stock has fluctuated within a day range of 149.02 USD to 152.08 USD, while its 52-week range spans from 77.58 USD to 156.92 USD.

What Is Merck&Co (MRK) Price Target According to Analysts?

The average 12-month price target for Merck&Co is 148.73 USD, with a high estimate of 186 USD and a low estimate of 105 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -0.54% Downside potential.

What Is the MRK Premarket Price?

MRK's last pre-market stock price is 148.92 USD. The pre-market share volume is 65,210.00, and the stock has decreased by -4.18, or -2.73%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.